Hypidone (developmental code name YL-0919) is an investigational serotonergic antidepressant which is under development for the treatment of major depressive disorder.[1][2][3][4][5] It acts as a serotonin reuptake inhibitor, 5-HT1A receptor partial agonist, and 5-HT6 receptor full agonist.[1][5] It is used as the hydrochloride salt.[2][5] As of January 2021, hypidone is in phase 2 clinical trials for major depressive disorder.[1]
Clinical data | |
---|---|
Other names | YL-0919; YL0919 |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
Chemical and physical data | |
Formula | C18H22N2O2 |
Molar mass | 298.386 g·mol−1 |
3D model (JSmol) |
|
| |
|